错配修复缺陷、微卫星不稳定性与生存:医学研究理事会辅助性胃癌输注化疗(MAGIC)试验的探索性分析
该研究为MAGIC试验的事后二次分析,评估可切除胃食管癌患者中错配修复缺陷(MMRD)与微卫星不稳定性(MSI)和总生存(OS)的关联。结果显示,仅手术组中高MSI或MMRD者OS未达到 vs 无此特征者20.5个月(HR 0.42,95%CI 0.15-1.15,P=0.09);化疗加手术组中高MSI或MMRD者OS 9.6个月 vs 无此特征者19.5个月(HR 2.18,95%CI 1.08-4.42,P=0.03)。
要点
- 仅手术组中,高MSI或MMRD者中位OS未达到 vs 无此特征者20.5个月(HR 0.42,P=0.09)。
- 化疗加手术组中,高MSI或MMRD者中位OS 9.6个月 vs 无此特征者19.5个月(HR 2.18,P=0.03)。
- 作者认为若经独立验证,术前活检检测MSI或MMRD或可用于筛选 perioperative 化疗患者。
核心结论
- 在MAGIC试验中,MMRD和高MSI在仅手术患者中与阳性预后效应相关,在化疗患者中与差异性阴性预后效应相关。
- 若经独立验证,术前活检确定的MSI或MMRD或可用于筛选患者接受perioperative化疗。
研究设计与样本
- MAGIC试验的二次事后分析,纳入1994年7月1日至2002年4月30日期间接受仅手术或perioperative化疗加手术治疗的可手术胃食管癌参与者。
- 评估肿瘤切片中错配修复蛋白mutL同源物1、mutS同源物2、mutS同源物6和PMS1同源物2的表达。
- 503例研究参与者中,303例有MSI结果可用(283例为微卫星稳定或低MSI,中位年龄62岁,男性219例(77.4%);20例为高MSI,中位年龄66岁,男性14例(70.0%))。
- 254例患者有MSI和MMR结果可用。
主要发现
- 仅手术组中,高MSI或MMRD者中位OS未达到(95%CI 11.5个月至未达到)vs 无高MSI且无MMRD者中位OS 20.5个月(95%CI 16.7-27.8个月;HR 0.42;95%CI 0.15-1.15;P=0.09)。
- 化疗加手术组中,高MSI或MMRD者中位OS 9.6个月(95%CI 0.1-22.5个月)vs 无高MSI且无MMRD者中位OS 19.5个月(95%CI 15.4-35.2个月;HR 2.18;95%CI 1.08-4.42;P=0.03)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI) are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early colon cancer. However, the effect of MMRD and MSI in curatively resected gastric cancer treated with perioperative chemotherapy is unknown. OBJECTIVE: To examine the association among MMRD, MSI, and survival in patients with resectable gastroesophageal cancer randomized to surgery alone or perioperative epirubicin, cisplatin, and fluorouracil chemotherapy in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. DESIGN, SETTING, AND PARTICIPANTS: This secondary post hoc analysis of the MAGIC trial included participants who were treated with surgery alone or perioperative chemotherapy plus surgery for operable gastroesophageal cancer from July 1, 1994, through April 30, 2002. Tumor sections were assessed for expression of the MMR proteins mutL homologue 1, mutS homologue 2, mutS homologue 6, and PMS1 homologue 2. The association among MSI, MMRD, and survival was assessed. MAIN OUTCOMES AND MEASURES: Interaction between MMRD and MSI status and overall survival (OS). RESULTS: Of the 503 study participants, MSI results were available for 303 patients (283 with microsatellite stability or low MSI [median age, 62 years; 219 males (77.4%)] and 20 with high MSI [median age, 66 years; 14 males (70.0%)]). A total of 254 patients had MSI and MMR results available. Patients treated with surgery alone who had high MSI or MMRD had a median OS that was not reached (95% CI, 11.5 months to not reached) compared with a median OS among those who had neither high MSI nor MMRD of 20.5 months (95% CI, 16.7-27.8 months; hazard ratio, 0.42; 95% CI, 0.15-1.15; P = .09). In contrast, patients treated with chemotherapy plus surgery who had either high MSI or MMRD had a median OS of 9.6 months (95% CI, 0.1-22.5 months) compared with a median OS among those who were neither high MSI nor MMRD of 19.5 months (95% CI, 15.4-35.2 months; hazard ratio, 2.18; 95% CI, 1.08-4.42; P = .03). CONCLUSIONS AND RELEVANCE: In the MAGIC trial, MMRD and high MSI were associated with a positive prognostic effect in patients treated with surgery alone and a differentially negative prognostic effect in patients treated with chemotherapy. If independently validated, MSI or MMRD determined by preoperative biopsies could be used to select patients for perioperative chemotherapy.
引用
- Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017. PMID: 28241187. doi:10.1001/jamaoncol.2016.6762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。